Sign In
Section Navigation
Common TitleATLANTIC
Official Title A Randomized Open-Label Strategic Study to Evaluate the Safety and Efficacy of 3 Different Convergent and Divergent Drug Combination Therapies in Anti-Retroviral Naive HIV-1 Infected Patients With CD4+ Counts Above 200/mm3
ClinicalTrials.gov NCT00002407
Treatments
Stavudine
Stavudine Zerit

Stavudine

Tradename:ZeritOther Names:d4TClass:Nucleoside Reverse Transcriptase Inhibitors (NRTI)
,
Indinavir
Indinavir Crixivan

Indinavir

Tradename:CrixivanOther Names:IDVClass:Protease Inhibitors (PI)
,
Nevirapine
Nevirapine Viramune

Nevirapine

Tradename:ViramuneOther Names:NVPClass:Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTI)
,
Didanosine
Didanosine Videx

Didanosine

Tradename:VidexOther Names:ddIClass:Nucleoside Reverse Transcriptase Inhibitors (NRTI)
Categories PharmacologyTreatment-NaiveAdverse Effects
Funding
IndustryBristol-Myers Squibb and Boehringer Ingelheim
References
  • van der Valk M, Kastelein JJ, Murphy RL, et al. Nevirapine-containing antiretroviral therapy in HIV-1 infected patients results in an anti-atherogenic lipid profile. AIDS. 2001;15:2407-14.
    [PubMed Abstract]
  • van Leeuwen R, Katlama C, Murphy RL, et al. A randomized trial to study first-line combination therapy with or without a protease inhibitor in HIV-1-infected patients. AIDS. 2003;17:987-99.
    [PubMed Abstract]

Share by e-mail

Since you've received 80% or better on this quiz, you may claim continuing education credit.

You seem to have a popup blocker enabled. If you want to skip this dialog please Always allow popup windows for the online course.